A recent report by Bain & Company and APACMed (a MedTech trade association located in Singapore) has issued a report on Asian MedTech companies’ growing appetite for ESG initiatives. According to this report, the Asia region has doubled its ESG policies compared... Read More
Ten years ago, China was making low-tech devices and generic drugs. This scenario has changed dramatically as China can now make sophisticated devices like drug-eluting stents and hip/knee replacements similar to the West and innovative drugs that Western drug companies are now... Read More
While robotic surgical devices have penetrated much of the US and Europe, future growth is expected to be strongest in Asia. It is estimated that Asian surgical robotic sales will hit $10 billion in 5 years. Asia’s quickly aging population and the... Read More
On May 20, known as International Clinical Trials Day in China, a number of Chinese hospitals and related groups provided an in-depth educational session to help enlighten Chinese patients about participating in local clinical trials. Over 30,000 Chinese attended these informational sessions,... Read More
While AI used in Healthcare is most prevalent in the US and China, a market research firm “Insights10” projects growth in this sector from $0.1 billion in 2022 to $2.11 billion by 2030 in Korea. The growth is fueled by the Korean... Read More
With over 275 million people, Indonesia is the world’s 4th largest country. Healthcare spending is expected to rise from about $35 per person in 2005 to over $270 per person by 2027. On July 11, the Indonesian House of Representatives announced a... Read More
According to a recent market research report by Triton Market Research, Asia’s CDX market was valued at $1.4 billion in 2022 and is likely to grow to $3.85 billion by 2030 with a CAGR of 13%. While CDX growth has already accelerated... Read More
Korea is gearing up to expand its own homegrown domestically produced medical device business. The country is hoping to develop and export more of its own medical devices internationally. In an effort to do this, a few weeks ago, Korea’s MFDS outlined... Read More
Everyone knows that the China drug market is very large. However, national and provincial tenders, Volume Based Procurement (VBP), the DRG system and other recent measures have significantly lowered pricing and reimbursements. To get drug reimbursement in China, a company needs to... Read More
While the West and Japan are prioritizing personalized medicine and the use of Companion Diagnostics (CDx) to determine which patients will benefit from specific drugs, development in China has been slow. CDx products in China are classified and regulated by existing medical... Read More